Computed tomography at every step: Long coronavirus disease

ArticleAçık Erişim

Özet

Background: Some patients continue to experience symptoms related to Coronavirus disease (COVID-19) after the acute phase of infection. Imaging studies, especially computed tomography (CT) of the chest, have gained importance since the beginning of the pandemic. CT can help diagnose COVID-19, assess the extent of pulmonary involvement, and predict the disease severity. We aimed to define the frequency of persistent symptoms and correlate their presence with the results of laboratory findings and the severity of the disease based on the findings of chest CT. Methods: We examined patients discharged from the hospital after treatment for COVID-19 and whose nasopharyngeal swab sample tested positive for severe acute respiratory syndrome coronavirus 2 after at least 4 weeks from the initial diagnosis. The patients were asked about the presence of persisting symptoms. In addition to the demographic data, laboratory results and severity levels seen on the chest CT were recorded. Results: In all, 116 patients were included in the study, of which 61 reported at least one persisting symptom (52.5%). The mean age of the study population was 48.90 ± 17.74 years. The persistent symptoms included shortness of breath, chest pain, cough, muscle weakness, dizziness, headache, fatigue, and palpitations. The mean CT severity score was 3.80 ± 0.38 and it was lower in patients without any persistent symptoms. Conclusions: Levels of C-reactive protein and fibrinogen, anemia, and female sex were associated with some of the persistent symptoms., the severity of the disease seen on CT was a successful predictor for the disease severity/prognosis and was also correlated with prolonged COVID infection and more persistent symptoms. © 2021 The Japanese Respiratory Society

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13373Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorAydin, Sonay
dc.contributor.authorUnver, Edhem
dc.contributor.authorKaravas, Erdal
dc.contributor.authorYalcin, Seven
dc.contributor.authorKantarci, Mecit
dc.date.accessioned2026-10-18T20:28:12.778762980Z
dc.date.available2026-10-18T20:28:12.778762980Z
dc.date.issued2021
dc.description.abstractBackground: Some patients continue to experience symptoms related to Coronavirus disease (COVID-19) after the acute phase of infection. Imaging studies, especially computed tomography (CT) of the chest, have gained importance since the beginning of the pandemic. CT can help diagnose COVID-19, assess the extent of pulmonary involvement, and predict the disease severity. We aimed to define the frequency of persistent symptoms and correlate their presence with the results of laboratory findings and the severity of the disease based on the findings of chest CT. Methods: We examined patients discharged from the hospital after treatment for COVID-19 and whose nasopharyngeal swab sample tested positive for severe acute respiratory syndrome coronavirus 2 after at least 4 weeks from the initial diagnosis. The patients were asked about the presence of persisting symptoms. In addition to the demographic data, laboratory results and severity levels seen on the chest CT were recorded. Results: In all, 116 patients were included in the study, of which 61 reported at least one persisting symptom (52.5%). The mean age of the study population was 48.90 ± 17.74 years. The persistent symptoms included shortness of breath, chest pain, cough, muscle weakness, dizziness, headache, fatigue, and palpitations. The mean CT severity score was 3.80 ± 0.38 and it was lower in patients without any persistent symptoms. Conclusions: Levels of C-reactive protein and fibrinogen, anemia, and female sex were associated with some of the persistent symptoms., the severity of the disease seen on CT was a successful predictor for the disease severity/prognosis and was also correlated with prolonged COVID infection and more persistent symptoms. © 2021 The Japanese Respiratory Society
dc.identifier.doi10.1016/j.resinv.2021.05.014
dc.identifier.eissn2212-5353
dc.identifier.endpage627
dc.identifier.issn2212-5345
dc.identifier.issue5
dc.identifier.pmcidPMC8238689
dc.identifier.pmid34210624
dc.identifier.scopus2-s2.0-85108948964
dc.identifier.startpage622
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13373
dc.identifier.volume59
dc.identifier.wosWOS:000689732200009
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofRespiratory Investigation
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCRP
dc.subjectCT severity
dc.subjectD dimer
dc.subjectPersistent symptom
dc.subjectPost-COVID
dc.subjectAdult
dc.subjectAged
dc.subjectCOVID-19
dc.subjectFemale
dc.subjectHumans
dc.subjectMiddle Aged
dc.subjectPandemics
dc.subjectSARS-CoV-2
dc.subjectSeverity of Illness Index
dc.subjectTomography, X-Ray Computed
dc.subjectC reactive protein
dc.subjectfibrinogen
dc.subjectadolescent
dc.subjectage distribution
dc.subjectArticle
dc.subjectclinical feature
dc.subjectcomputer assisted tomography
dc.subjectcontrolled study
dc.subjectcoronavirus disease 2019
dc.subjectcoughing
dc.subjectdemography
dc.subjectdisease duration
dc.subjectdisease severity
dc.subjectdizziness
dc.subjectdyspnea
dc.titleComputed tomography at every step: Long coronavirus disease
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus10
rdl.citation.wos12
rdl.departmentDepartment of Radiology, Erzincan University, Erzincan, Turkey. Electronic address: sonay.aydin@erzincan.edu.tr. | Department of Chest Disease, Erzincan University, Erzincan, Turkey. | Department of Radiology, Erzincan University, Erzincan, Turkey. | Department of Radiology, Erzincan University, Erzincan, Turkey
rdl.departmentDepartment of Radiology, Atatürk University, Erzurum, Turkey.
rdl.oa.statusgreen
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexEmerging Sources Citation Index (ESCI)